Clinical Trials

Overview

NMD-670

NMD-670 is a small molecule that increases muscle contractions, which leads to an increase in muscle strength and function, which could be beneficial to people living with SMA. Preclinical studies demonstrated that NMD670 enhances neuromuscular communication and improves skeletal muscle function. NMD Pharma is developing this molecule as an oral treatment for neuromuscular diseases, including SMA and myasthenia gravis.

NMD-670 will be trialled in a phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adult patients with SMA Type 3. The study is an international multicentre study and will include sites in Europe and North America, with first dosing of patients expected to take place in Q1 2023.

Method of Action

NMD-670 is a small molecule that increases muscle contractions by inhibiting CIC-1, a chloride channel that causes muscles to relax. In doing so, the molecule is thought to increase muscle strength and function.

Trial of NMD-670

Trial Name
NMD-670
Age:
18 to 60 years old.
Aim:
To evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with SMA type 3.
Status:
Recruiting
Locations:
Belgium, Canada, Denmark, Germany, Italy, Netherlands, Spain, USA
Identifier:
NCT05794139

Press releases